P J. Van Den Berkmortel

Sittard, LI, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Preference versus protocol: oncology clinicians' perspectives on central venous access for administration of chemotherapy in pancreatic cancer.

Preference versus protocol: oncology clinicians' perspectives on central venous access for administration of chemotherapy in pancreatic cancer.

Journal: ESMO gastrointestinal oncology

Published: March 11, 2026

Clinical predictors of pseudoprogression in glioblastoma: a retrospective cohort analysis.

Clinical predictors of pseudoprogression in glioblastoma: a retrospective cohort analysis.

Journal: Journal of neuro-oncology

Published: August 22, 2025

Induction therapy with BRAF/MEK inhibitors versus upfront ipilimumab/nivolumab in poor prognostic advanced melanoma.

Induction therapy with BRAF/MEK inhibitors versus upfront ipilimumab/nivolumab in poor prognostic advanced melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 10, 2025

Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry.

Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 28, 2025

Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis.

Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis.

Journal: British journal of cancer

Published: January 13, 2025

Corrigendum to "Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry" [Eur. J. Cancer 212, 2024, 115056].

Corrigendum to "Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry" [Eur. J. Cancer 212, 2024, 115056].

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 28, 2024

The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial.

The prognostic and predictive value of the luminal-like subtype in hormone receptor-positive breast cancer: an analysis of the DATA trial.

Journal: ESMO open

Published: October 12, 2024

Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy.

Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy.

Journal: British journal of cancer

Published: October 04, 2024

Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma.

Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma.

Journal: Immuno-oncology technology

Published: July 24, 2024

Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry.

Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 21, 2024

Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.

Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.

Journal: BMC cancer

Published: January 30, 2024

Seasonal variation of anti-PD-1 outcome in melanoma-Results from a Dutch patient cohort.

Seasonal variation of anti-PD-1 outcome in melanoma-Results from a Dutch patient cohort.

Journal: Pigment cell & melanoma research

Published: February 28, 2023

Showing 1-12 of 21

Last Updated: 09/26/2026